Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis

Arthritis Research and Therapy

Volumn 14, Issue 1, 2012, Pages

  Kezic, Jelena M ^a,b,c   Glant, Tibor T ^d   Rosenbaum, James T ^a,e   Rosenzweig, Holly L ^a,e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROTEOGLYCAN; T LYMPHOCYTE RECEPTOR; AGGRECAN; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKYLOSING SPONDYLITIS; ANTERIOR EYE SEGMENT; ARTICLE; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; INTRAVITAL VIDEOMICROSCOPY; LEUKOCYTE; MICROSCOPY; MOUSE; NONHUMAN; PHOTORECEPTOR; POSTERIOR EYE SEGMENT; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; TH17 CELL; UVEITIS; VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHOTORECEPTOR CELL; SPONDYLARTHRITIS; TRANSGENIC MOUSE;

AGGRECANS; ANIMALS; ANTIBODIES, NEUTRALIZING; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; PHOTORECEPTOR CELLS, VERTEBRATE; RECEPTORS, ANTIGEN, T-CELL; SPONDYLARTHRITIS; T-LYMPHOCYTES; UVEITIS;

EID: 84856033476     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3697     Document Type: Article

References (47)

1. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990, 14:303-308. 10.1007/BF00163549, 2249907.
2. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008, 67:955-959.
3. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007, 369:1379-1390. 10.1016/S0140-6736(07)60635-7, 17448825.
4. Kezic JM, Davey MP, Glant TT, Rosenbaum JT, Rosenzweig HL. IFNγ regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondyloarthritis. Arthritis Rheum 2011, [Epub ahead of print].
5. Zou J, Appel H, Rudwaleit M, Thiel A, Sieper J. Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis. Ann Rheum Dis 2005, 64:722-729. 10.1136/ard.2004.024455, 1755485, 15539415.
6. Glant TT, Radacs M, Nagyeri G, Olasz K, Laszlo A, Boldizsar F, Hegyi A, Finnegan A, Mikecz K. Proteoglycan-induced arthritis and recombinant human proteoglycan aggrecan G1 domain-induced arthritis in BALB/c mice resembling two subtypes of rheumatoid arthritis. Arthritis Rheum 2011, 63:1312-1321. 10.1002/art.30261, 21305522.
7. Glant TT, Cs-Szabo G, Nagase H, Jacobs JJ, Mikecz K. Progressive polyarthritis induced in BALB/c mice by aggrecan from normal and osteoarthritic human cartilage. Arthritis Rheum 1998, 41:1007-1018. 10.1002/1529-0131(199806)41:6<1007::AID-ART7>3.0.CO;2-6, 9627010.
8. Glant TT, Finnegan A, Mikecz K. Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics. Crit Rev Immunol 2003, 23:199-250. 10.1615/CritRevImmunol.v23.i3.20, 14584879.
9. Bardos T, Szabo Z, Czipri M, Vermes C, Tunyogi-Csapo M, Urban RM, Mikecz K, Glant TT. A longitudinal study on an autoimmune murine model of ankylosing spondylitis. Ann Rheum Dis 2005, 64:981-987. 10.1136/ard.2004.029710, 1755557, 15640265.
10. Buzas EI, Brennan FR, Mikecz K, Garzo M, Negroiu G, Hollo K, Cs-Szabo G, Pintye E, Glant TT. A proteoglycan (aggrecan)-specific T cell hybridoma induces arthritis in BALB/c mice. J Immunol 1995, 155:2679-2687.
11. Cao Y, Doodes PD, Glant TT, Finnegan A. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol 2008, 180:922-930.
12. Finnegan A, Grusby MJ, Kaplan CD, O'Neill SK, Eibel H, Koreny T, Czipri M, Mikecz K, Zhang J. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol 2002, 169:3345-3352.
13. Berlo SE, Guichelaar T, Ten Brink CB, van Kooten PJ, Hauet-Broeren F, Ludanyi K, van Eden W, Broeren CP, Glant TT. Increased arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice. Arthritis Rheum 2006, 54:2423-2433. 10.1002/art.22013, 16869010.
14. Yeremenko N, Baeten D. IL-17 in spondyloarthritis: is the T-party over?. Arthritis Rheum 2011, 13:115.
15. Song IH, Poddubnyy D. New treatment targets in ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol 2011, 23:346-351. 10.1097/BOR.0b013e328346f7fb, 21508843.
16. Glant TT, Mikecz K. Proteoglycan aggrecan-induced arthritis: a murine autoimmune model of rheumatoid arthritis. Methods Mol Med 2004, 102:313-338.
17. Rosenzweig HL, Martin TM, Jann MM, Planck SR, Davey MP, Kobayashi K, Flavell RA, Rosenbaum JT. NOD2, the gene responsible for familial granulomatous uveitis, is essential in a mouse model of muramyl dipeptide-induced uveitis. Invest Ophthalmol Vis Sci 2008, 49:1518-1524. 10.1167/iovs.07-1174, 2430189, 18385071.
18. Becker MD, Nobiling R, Planck SR, Rosenbaum JT. Digital video-imaging of leukocyte migration in the iris: intravital microscopy in a physiological model during the onset of endotoxin-induced uveitis. J Immunol Methods 2000, 240:23-37. 10.1016/S0022-1759(00)00165-4, 10854598.
19. Rosenzweig HL, Jann MJ, Vance EE, Planck SR, Rosenbaum JT, Davey MP. Nucleotide-binding oligomerization domain 2 and Toll-like receptor 2 function independently in a murine model of arthritis triggered by intraarticular peptidoglycan. Arthritis Rheum 2010, 62:1051-1059. 2945367, 20131263.
20. Rosenzweig H, Galster K, Planck S, Rosenbaum JT. NOD1 expression in the eye and functional contribution to IL-1{beta} dependent ocular inflammation in mice. Invest Ophthalmol Vis Sci 2009, 50:1746-1753. 3086269, 19074813.
21. Rosenzweig HL, Jann MM, Glant T, Martin TM, Planck SR, Van Eden W, Van Kooten PJ, Flavell RA, Kobayashi K, Rosenbaum JT, Davey MP. Activation of nucleotide oligomerization domain 2 exacerbates a murine model of proteoglycan-induced arthritis. J Leukoc Biol 2009, 85:711-718. 10.1189/jlb.0808478, 2718807, 19129483.
22. Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007, 74:304-305. 10.1016/j.jbspin.2006.11.005, 17369068.
23. Wang X, Lin Z, Wei Q, Jiang Y, Gu J. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int 2009, 29:1343-1347. 10.1007/s00296-009-0883-x, 19247658.
24. Finnegan A, Mikecz K, Tao P, Glant TT. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol 1999, 163:5383-5390.
25. Doodes PD, Cao Y, Hamel KM, Wang Y, Farkas B, Iwakura Y, Finnegan A. Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol 2008, 181:329-337. 2495052, 18566398.
26. Doodes PD, Cao Y, Hamel KM, Wang Y, Rodeghero RL, Mikecz K, Glant TT, Iwakura Y, Finnegan A. IFN-gamma regulates the requirement for IL-17 in proteoglycan-induced arthritis. J Immunol 2010, 184:1552-1559. 10.4049/jimmunol.0902907, 2846113, 20028652.
27. Feltkamp TEW. HLA B27, acute anterior uveitis, and ankylosing spondylitis. Adv Inflamm Res 1985, 9:211-216.
28. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2 m: an animal model of HLA-B27-associated human disorders. Cell 1990, 63:1099-1112. 10.1016/0092-8674(90)90512-D, 2257626.
29. Baggia S, Lyons J, Angell E, Barkhhizen A, Han YB, Planck SR, Taurog JD, Rosenbaum JT. A novel model of bacterially-induced acute anterior uveitis in rats and the lack of effect from HLA B27 expression. J Investig Med 1997, 45:295-301.
30. Zochling J, Van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, Dougados M, Geher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Oliveieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Bohm H, van Royen BJ, Braun J, , . 'Assessment in AS' international working group, European League Against Rheumatism ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006, 65:442-452. 10.1136/ard.2005.041137, 1798102, 16126791, 'Assessment in AS' international working group, European League Against Rheumatism.
31. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010, 11:180-210.
32. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001, 45:252-257. 10.1002/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5, 11409666.
33. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007, 56:3248-3252. 10.1002/art.22918, 17907169.
34. Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, Bowman EP, Sgambellone NM, Chan CC, Caspi RR. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008, 205:799-810. 10.1084/jem.20071258, 2292220, 18391061.
35. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007, 13:711-718. 10.1038/nm1585, 17496900.
36. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, , Durez P, Tak PP, Gomez-Eino JJ, , Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD, , Rose K, Haider A, Di Padova F. Psoriasis Study Group, Rheumatoid Arthritis Study Group, Uveitis Study Group Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2:52ra72. 10.1126/scitranslmed.3001107, 20926833, Psoriasis Study Group, Rheumatoid Arthritis Study Group, Uveitis Study Group.
37. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010, 10:479-489. 10.1038/nri2800, 20559326.
38. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol 2011, 23:1-7. 10.1016/j.coi.2010.12.001, 21185707.
39. Moran EM, Heydrich R, Ng CT, Saber TP, McCormick J, Sieper J, Appel H, Fearon U, Veale DJ. IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLos One 2011, 6:e24048. 10.1371/journal.pone.0024048, 3161104, 21887369.
40. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008, 38:2636-2649. 10.1002/eji.200838535, 18958872.
41. Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J. Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011, 13:R95. 10.1186/ar3370, 3218910, 21689402.
42. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009, 373:633-640. 10.1016/S0140-6736(09)60140-9, 19217154.
43. Zhu F, Wang Q, Guo C, Wang X, Cao X, Shi Y, Gao F, Ma C, Zhang L. IL-17 induces apoptosis of vascular endothelial cells - a potential mechanism for human acute coronary syndrome. Clin Immunol 2011, 141:152-160. 10.1016/j.clim.2011.07.003, 21872532.
44. Cunnusamy K, Chen PW, Niederkorn JY. IL-17 promotes immune privilege of corneal allografts. J Immunol 2010, 185:4651-4658. 10.4049/jimmunol.1001576, 3132880, 20844197.
45. Kirshberg S, Izhar U, Amir G, Demma J, Vernea F, Beider K, Shlomai Z, Wald H, Zamir G, Shapira OM, Peled A, Wald O. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS One 2011, 6:e24856. 10.1371/journal.pone.0024856, 3174223, 21949768.
46. Zhang Z, Zhong W, Spencer D, Chen H, Lu H, Kawaguchi T, Rosenbaum JT. Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11.10 mice. Cytokine 2009, 46:79-91. 10.1016/j.cyto.2008.12.019, 2745339, 19254849.
47. Jiang G, Ke Y, Sun D, Han G, Kaplan HJ, Shao H. Reactivation of uveitogenic T cells by retinal astrocytes derived from experimental autoimmune uveitis-prone B10RIII mice. Invest Ophthalmol Vis Sci 2008, 49:282-289. 10.1167/iovs.07-0371, 2567872, 18172104.